---
title: "Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302453448.md"
description: "Arcus Biosciences presented promising results for its kidney cancer treatment on Tuesday, which competitors Merck have also been developing. Following this announcement, the shares of Arcus Biosciences experienced a significant increase, rebounding from a premarket decline. This sudden surge in share value was driven by the positive reception of the Merck-rivaling cancer treatment reveal."
datetime: "2026-10-20T17:15:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302453448.md)
  - [en](https://longbridge.com/en/news/302453448.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302453448.md)
generator: "portal-rs"
---

# Arcus Reverses Course, Surging On Its Merck-Rivaling Cancer Reveal

Arcus Biosciences presented promising results for its kidney cancer treatment on Tuesday, which competitors Merck have also been developing. Following this announcement, the shares of Arcus Biosciences experienced a significant increase, rebounding from a premarket decline. This sudden surge in share value was driven by the positive reception of the Merck-rivaling cancer treatment reveal.

### Related Stocks

- [RCUS.US](https://longbridge.com/en/quote/RCUS.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News](https://longbridge.com/en/news/303130364.md)
- [Arcus rises as analysts cheer ARC-20 platform data for kidney cancer drug](https://longbridge.com/en/news/302448893.md)
- [Arcus Biosciences Closes $269.7 Million Stock Offering](https://longbridge.com/en/news/302923681.md)
- [Nextpower Inc (NXT) Gets a Buy from Wells Fargo](https://longbridge.com/en/news/303840692.md)
- [RCUS: Casdatifan data support its potential as a backbone across kidney cancer treatment lines](https://longbridge.com/en/news/302426624.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**